China SXT Pharmaceuticals, Inc.
SXTC · NASDAQ
9/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.04 | 0.00 |
| FCF Yield | 0.00% | -8.14% | -4.99% | -28.77% |
| EV / EBITDA | 0.00 | 10.88 | 7.10 | 22.05 |
| Quality | ||||
| ROIC | 0.00% | -6.22% | -6.22% | -1.28% |
| Gross Margin | 0.00% | 25.53% | 25.53% | 16.25% |
| Cash Conversion Ratio | 0.40 | 0.40 | 1.69 | 1.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.19% | – | – | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 27.04% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 16.88 | 16.88 | 30.33 |
| Interest Coverage | 0.00 | -4.38 | -4.38 | -3.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.41 | 0.30 | 0.22 |
| Cash Conversion Cycle | 0.00 | 287.69 | 249.26 | 341.87 |